To include your compound in the COVID-19 Resource Center, submit it here.

June 4 ASCO Quick Takes: Sarcoma data for Aadi's nab-sirolimus; plus c-MET inhibitor data for NSCLC

Aadi's ABI-009 leads to 42% ORR in rare sarcoma
Aadi Bioscience Inc. (Pacific Palisades, Calif.) reported at ASCO Monday that nab-sirolimus (ABI-009) led to a

Read the full 245 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE